AN 448 Sandoz (Mazindol) in the treatment of obesity
- PMID: 775265
AN 448 Sandoz (Mazindol) in the treatment of obesity
Abstract
The clinical value of a new anorectic agent, AN 448 Sandoz (mazindol) has been assessed in a double-blind trial against placebo in 50 obese patients. Over the 12 weeks of the trial, mazindol was shown to be an effective adjunct to carbohydrate restriction in weight reduction.
Similar articles
-
A double blind controlled trial of a new anorectic agent AN448.N Z Med J. 1975 Jun 25;81(542):546-9. N Z Med J. 1975. PMID: 1099491 Clinical Trial.
-
Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.Diabete Metab. 1978 Sep;4(3):193-9. Diabete Metab. 1978. PMID: 361463 Clinical Trial.
-
[Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].Rev Med Chil. 1977 Jun;105(6):375-9. Rev Med Chil. 1977. PMID: 331428 Clinical Trial. Spanish. No abstract available.
-
Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.Am J Clin Nutr. 1992 Jan;55(1 Suppl):199S-202S. doi: 10.1093/ajcn/55.1.199s. Am J Clin Nutr. 1992. PMID: 1728834 Review.
-
Clinical studies with mazindol.Obes Res. 1995 Nov;3 Suppl 4:549S-552S. doi: 10.1002/j.1550-8528.1995.tb00226.x. Obes Res. 1995. PMID: 8697057 Review.
Cited by
-
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.Clinics (Sao Paulo). 2017 May;72(5):317-324. doi: 10.6061/clinics/2017(05)10. Clinics (Sao Paulo). 2017. PMID: 28591345 Free PMC article.
-
The role of drugs in the treatment of obesity.Drugs. 1981 May;21(5):362-73. doi: 10.2165/00003495-198121050-00004. Drugs. 1981. PMID: 7014176 Review. No abstract available.
-
The anorectic action of mazindol.Ir J Med Sci. 1978 Aug;147 Suppl 1:66-70. doi: 10.1007/BF02947908. Ir J Med Sci. 1978. PMID: 689855 No abstract available.